Corvus Pharmaceuticals Announces Board Changes, Including Audit Committee Chair Resignation
Summary
Corvus Pharmaceuticals announced the resignation of its long-serving Audit Committee Chairperson and the appointment of a new director with a scientific background.
Key Events
-
Audit Committee Chair Resigns
Scott Morrison, a director for over a decade and Chairperson of the Audit Committee, resigned from the Board effective April 23, 2026.
-
New Director Appointed
Andrew C. Chan, M.D., Ph.D., was appointed to the Board as a Class II director and to the Nominating Committee, effective April 23, 2026.
-
New Director Compensation
Dr. Chan will receive a $35,000 annual Board retainer, an initial stock option grant for 30,000 shares, and $4,000 for Nominating Committee service.
Analysis
Corvus Pharmaceuticals reported the resignation of Scott Morrison, a long-serving director and Chairperson of the Audit Committee, effective April 23, 2026. Concurrently, Andrew C. Chan, M.D., Ph.D., was appointed to the Board and the Nominating Committee. While the addition of a new director with a strong scientific background is a positive for the company's expertise, the departure of a key committee chair after over a decade of service represents a notable change in governance and could raise questions about continuity, even if the departure appears amicable.
At the time of this filing, CRVS was trading at $16.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $3.17 to $26.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.